Sibylla is a preclinical stage company focused on developing new small molecule degraders with a novel mechanism of action for unmet medical needs. PPI-FIT platform is powered by computer simulations and AI / ML methods, enabling the discovery and development of compounds that induce the degradation of a target protein by interfering with its folding pathway. By exploiting this new paradigm, Sibylla harnesses the identification and development of small molecules acting on targets involved in different types of diseases.